

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07C 401/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/01811</b> <b>(43) International Publication Date:</b> 25 January 1996 (25.01.96)
<b>(21) International Application Number:</b> PCT/US95/07595 <b>(22) International Filing Date:</b> 22 June 1995 (22.06.95) <b>(30) Priority Data:</b> 08/272,665 11 July 1994 (11.07.94) US <b>(71) Applicant:</b> THE JOHNS-HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, MD 21218 (US). <b>(72) Inventor:</b> POSNER, Gary, H.; 3216 Timberfield Lane, Baltimore, MD 21208 (US). <b>(74) Agents:</b> KOKULIS, Paul, N. et al.; Cushman Darby & Cushman L.L.P., 1100 New York Avenue, N.W., Washington, DC 20005 (US).		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> 2-SUBSTITUTED 1,25-DIHYDROXYVITAMIN D <sub>3</sub> DERIVATIVES  <b>(57) Abstract</b>  Vitamin D <sub>3</sub> analogues which include a 2-substituted alcohol or fluoride are described. The preferred alcohol substituent is exemplified by the structural formula $-(CH_2)_4OH$ and the preferred fluoride substituents by the structural formulas $-(CH_2)_3F$ and $-(CH_2)_4F$ . Methods for the preparation of a vitamin D <sub>3</sub> analogue which includes a 2-substituted alcohol or fluoride starting with 2+4-cycloaddition of commercially available methyl 2-pyrone-3-carboxylate are also described.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**2-SUBSTITUTED 1,25-DIHYDROXYVITAMIN D<sub>3</sub> DERIVATIVES****BACKGROUND OF THE INVENTION**

The present invention relates to novel  
5 biologically active vitamin D<sub>3</sub> analogues which  
include an alcohol or fluoride substituent in the  
2-position and methods for their preparation.


**FIELD OF THE INVENTION**

Vitamin D<sub>3</sub> analogues have been recognized as  
10 having important biological activities. It is  
known, for example, that vitamin D<sub>3</sub> analogues can  
be used to control calcium and phosphate  
metabolism.

It is also known that such analogues are  
15 useful for inducing cell differentiation and for  
inhibiting undesired cell proliferation. For  
example, it is well recognized that vitamin D<sub>3</sub>  
produces 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (calcitriol)  
during normal metabolism. Calcitriol is a potent  
20 regulator of cell differentiation and  
proliferation as well as intestinal calcium and  
phosphorus absorption and bone calcium  
mobilization. Calcitriol is also known to affect

the immune system and this compound, as well as a variety of synthetic vitamin D<sub>3</sub> derivatives have been used in practical, clinical chemotherapy of such diverse human illnesses as osteoporosis, cancer, immunodeficiency syndromes and skin disorders such as dermatitis and psoriasis. However, major research efforts are underway in an effort to prepare vitamin D<sub>3</sub> analogues as drugs in which calcitropic activity is effectively separated from cell growth regulation.

Calcitriol may be structurally represented as follows:





The upper and lower ring portions of calcitriol may be called, for ease of reference, the C/D-ring and A-ring, respectively.

**DESCRIPTION OF THE RELATED ART**

Especially for post-menopausal women, osteoporosis is a very serious illness that causes physical deformity and high susceptibility to bone (e.g., hip) fractures. In the general population aged above 65 years, osteoporosis ranks third to heart disease and cancer in terms of prevalence<sup>1</sup>. It is estimated that 30% of women at 75 years and 40% of women at 85 years have abnormal bone loss<sup>2</sup>. Calcitriol is being used, especially in Japan where dietary intake of calcium is low, for treatment of osteoporosis<sup>3</sup>. The Chugai Pharmaceutical Company has developed ED-71 (1) as a synthetic derivative of calcitriol, having a better therapeutic index than calcitriol<sup>4</sup>. This 28-(3'-hydroxypropyloxy)-calcitriol has a two-fold stronger binding affinity to the rat plasma vitamin D-binding protein (DBP) than does calcitriol, suggesting that it circulates in the plasma with a longer half-life than calcitriol<sup>4</sup>. Furthermore, in animal models with osteoporosis, ED-71(1) is more effective than calcitriol<sup>4</sup>.

To probe structure-medicinal activity relationships in the hope of preparing a new osteoporosis drug with an even better therapeutic index than ED-71(1), we targeted the 2-carba-analogues 2 and 3, structurally represented below.


These analogues were chosen because replacing one oxygen atom by a methylene group, a relatively small change in a large steroid molecule, was anticipated, based on the current working model for receptor binding of ED-71(1)<sup>4</sup>, not to interfere with such critical receptor binding. also, these analogues were chosen for chemical reasons, probing whether recently developed Diels-Alder methodology<sup>5</sup> using 2-pyrones and monosubstituted alkenes could be extended to 1,2-disubstituted alkene dienophiles with reliable and faithful transfer of olefin geometry ultimately into the stereochemical relationships at the 1- and 2-positions of the steroid targets. We record here the results of these chemical explorations and biological evaluations.



## SUMMARY OF THE INVENTION

The present invention is for a vitamin D<sub>3</sub> analogue which includes a 2-substituted alcohol or fluoride. The preferred alcohol substituent is exemplified by the structural formula  $-(CH_2)_4OH$  and the preferred fluoride substituents by the structural formulas  $-(CH_2)_3F$  and  $-(CH_2)_4F$ .

The preferred diastereomers of the 2-substituted  $-(CH_2)_4OH$  are represented by the following structural formulas:



The present invention is also for the related method of preparation of a vitamin D<sub>3</sub> analogue which includes a 2-substituted alcohol or fluoride starting with 2+4-cycloaddition of commercially available methyl 2-pyrone-3-carboxylate.

Diastereomeric 2-substituted calcitriol analogues were prepared in only eleven chemical operations, starting with 2+4-cycloaddition of commercially available methyl

5 2-pyrone-3-carboxylate. Highlights of this convergent and stereo controlled synthetic approach are as follows: (1) retention of reactant dienophile geometry in the product bicyclic lactone, characteristic of a concerted

10 inverse-electron-demand Diels-Alder cycloaddition; (2) an improved decarboxylation procedure involving chemospecific allyloxide opening of a lactone ring in the presence of a methyl ester and then non-high pressure palladium-promoted allylic

15 ester decarboxylation; and (3) use of the enantiomerically pure C,D-ring chiron 14 to resolve racemic A-ring phosphine oxide 13.

**DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED  
EXEMPLARY EMBODIMENTS**


20 Uncatalyzed Diels-Alder cycloadditions between highly polarized dienes and dienophiles can occur step-wise rather than in the usual concerted fashion<sup>6</sup>. To probe this issue within the context of inverse-electron-demand Diels-Alder

25 cycloadditions using 2-pyrones substituted at the 3-position with highly electron-withdrawing (e.g.






3-sulfonyl, 3-acyl) substituents<sup>5</sup>, 3-p-toluenesulfonyl-2-pyrone and 1,2-disubstituted alkenes **4E** and separately **4Z** were placed under high pressure. In both of these electronically matched cases, the electron-poor 2-pyrone diene and the electron-rich vinylic ether cycloadded to produce isolable bicyclic lactone adducts without undesirable and often-encountered extrusion of CO<sub>2</sub> (Scheme I)

10           The most important aspect of these Diels-Alder reactions from a mechanistic viewpoint is that the cycloadducts retained the stereochemical information in the reactant vinylic ethers: dienophile **4E** led exclusively to trans-4,5-oriented products **5a** and **5b**, whereas dienophile **4Z** led exclusively to cis-4,5-oriented products **6a** and **6b**. Therefore, these polarized 2+4-cycloadditions must occur in a concerted rather than in a step-wise fashion<sup>6</sup>. The assignments of the 4,5-positional relationships were based on extensive precedent<sup>5</sup>, and the assignments of the 4,5-stereochemical relationships were based on the match of the 400 MHz <sup>1</sup>H NMR J<sub>4,5</sub> coupling constants with those calculated using the Karplus equation for energy-minimized structures generated using Chem-3D (Scheme I)<sup>7</sup>. Bicyclic lactone **6a**, the very major cycloadduct, differed in a characteristic way<sup>5</sup> from bicyclic lactone **6b** in terms of the

**SCHEME I**


chemical shift of the bridgehead hydrogen atom ( $\delta$  4.98 vs. 5.04) and the chemical shift of the C<sub>4</sub> hydrogen atom ( $\delta$  4.55 vs. 3.83). Also, irradiation of the C<sub>5</sub> hydrogen atom of lactone 6a caused an 11 % nOe on the C<sub>4</sub> hydrogen atom. The large discrepancy between the observed and the calculated J<sub>4,5</sub> coupling constant for cis-4.5-disubstituted bicyclic adduct 6b was of considerable concern. Therefore, a series of similar cis-4.5-disubstituted bicyclic lactones was prepared. Examination of their J<sub>4,5</sub> coupling constants (Table I) showed a very subtle effect of the nature of the substituents on this magnitude of the vicinal coupling constant. For example, the cycloadduct derived from the 6-membered cyclic vinyl ether showed J<sub>4,5</sub>=0 Hz (entry 2), whereas that derived from the 5-membered cyclic vinyl ether showed J<sub>4,5</sub>=8.5 Hz (entry 3). Finally, based on literature analogies in which E-alkenes underwent 2+4-cycloadditions more easily than Z-alkenes<sup>6e-g</sup>, we were surprised to find that vinylic ether geometric isomer 4Z reacted considerably faster than isomer 4E with 3-tolysufonyl-2-pyrone. Whereas vinylic ether isomer 4Z yielded almost exclusively the endo-cycloadduct 6a, as expected from previous results<sup>5</sup>, vinylic ether isomer 4E gave a 1:2 mixture of cycloadducts 5a:5b.

**TABLE I****<sup>1</sup>H NMR Data for Several *cis*-4,5-Disubstituted Bicycloadducts**

<u>Entry</u>	<u>Compound</u>	<u>J<sub>4,5</sub> (Hz)</u>
1		0
2		0
3		8.5


From a synthesis viewpoint, cycloadducts 5 and 6 turned out to be disappointing. Despite close structural similarity with other bridgehead-substituted toluenesulfonyl cycloadducts and related cyclohexene systems that underwent smooth reductive-desulfonylation<sup>8</sup>, we were unsuccessful using a variety of conditions (e.g., Al-Hg, Na-Hg, Raney nickel, Li/NH<sub>3</sub>) to effect high-yielding reductive-desulfonylation. Also, it was anticipated that ultimate conversion of the methyl ether functionality into the desired alcohol group would be more difficult than deprotection of a silyl ether. Therefore, silylated vinylic ether 7Z, prepared according to literature precedent as illustrated in Scheme II<sup>9</sup>, and commercially available methyl 2-pyrone-3-carboxylate were subjected to high pressure cycloaddition (eq. 1).

Bicycloadduct 8 was the major product, isolated on gram scale in 60% yield, with the oxygen substituted at position-4, as expected based on the polar nature of the Diels-Alder cycloaddition and also on literature precedent<sup>5</sup>, with a cis-4,5-stereochemical relationship. This stereochemical outcome was expected based on the results in Scheme I with the 3-sulfonyl-2-pyrone and was confirmed by the observed large <sup>1</sup>H NMR J<sub>4,5</sub> coupling constant (8.6 Hz)<sup>7</sup> and by the characteristic chemical shifts of the bridgehead

SCHEME II

hydrogen atom at  $\delta$  5.1 and the C<sub>4</sub> hydrogen atom at  
 $\delta$  4.7. Also, irradiation of the C<sub>5</sub> hydrogen atom  
caused a 14% nOe on the C<sub>4</sub> hydrogen atom,  
confirming their cis-4,5-relationship. We have  
5 not succeeded in preparing cleanly the isomeric  
silylated vinylic ether 7E for cycloaddition with  
methyl 2-pyrone-3-carboxylate.

Having served its chemical function of  
activating the pyrone diene (the unsubstituted  
10 parent 2-pyrone is unreactive)<sup>5d,10</sup> for  
cycloaddition with the electron-rich vinylic ether  
7Z, the bridgehead carboxylate ester group in  
bicyclic lactone adduct 8 had to be removed. To  
complement our two-step lactone methanolysis and  
15 high-pressure procedure for this type of  
decarboxylation<sup>11</sup>, we report now a new and more  
convenience (i.e., not high pressure) two-step  
protocol (Scheme III). Although bicyclic lactone  
methyl ester 8 has two ester carbonyl groups, it  
20 was gratifying to find that the lactone ring was  
chemospecifically attacked by lithium allyloxide  
to produce mixed methyl allyl malonate 9 in 75%  
yield. In accord with literature precedent<sup>12</sup>,  
allyl ester 9 was smoothly decarboxylated using  
25 palladium acetate; an unexpected but desired  
benefit of this procedure was conjugation of the  
cyclohexene double bond, giving the contiguously

SCHEME III



tetrasubstituted cyclohexene 10 in 92% yield  
(Scheme III).

Without any surprises, highly functionalized  
cyclohexene alcohol ester 10 was O-silylated and  
5 then reduced to form allylic alcohol 11 (Scheme  
IV). One flask Claisen rearrangement followed by  
spontaneous thermal sulfoxide elimination was  
achieved using our sulfinylated ortho ester  
protocol<sup>13</sup> giving an unusually favorable >10:1 Z:E  
10 ratio of dienolate esters from which the desired Z-  
dienolate 12 was isolated by chromatography in 80%  
yield.

Established reactions as outlined in Scheme  
IV below provided the crucial, fully O-protected,  
15 racemic, A-ring phosphine oxide 13. Lythgoe-type  
coupling<sup>14</sup> of the conjugate base of phosphine oxide  
13, generated using phenyllithium<sup>15</sup>, with C,D-ring  
ketone 14 of natural absolute configuration  
produced O-silylated derivatives of diastereomeric  
20 2-(4'-hydroxylated) calcitriol analogues 3 and 3',  
isolated in 50% yield.


Fluoride-induced cleavage of the silyl  
protecting groups proceeded easily at three of the  
four silylated alcohol groups; desilylation at the  
25 C<sub>1</sub> secondary alcohol position, however, was  
unexpectedly slow, requiring considerably more  
vigorous reaction conditions.

In another context<sup>16</sup>, we have observed that the C<sub>1</sub> secondary alcohol unit in calcitriol is chemically less reactive than the C<sub>3</sub> secondary alcohol toward esterifying reagents.

5 Nevertheless, fluoride-assisted quadruple desilylation under more vigorous conditions eventually yielded the desired calcitriol analogues 3 and 3'.


Easy HPLC separation gave each diastereomer  
10 in enantiomerically pure form. Tentative assignments of stereochemistry to diastereomers 3 and 3' were made by <sup>1</sup>H NMR in analogy with closely related calcitriol analogues; in diastereomeric pairs differing only by inversions of  
15 stereochemistry at positions 1-3 but not in the C,D-ring or in the side chain, the 1 $\alpha$ -substituted diastereomer characteristically showed a lower field absorption for the C<sub>18</sub>-methyl group and for one proton of the C<sub>19</sub>-methylene group (Table II).

TABLE II.


<sup>1</sup>H NMR  
Chemical Shift  
( $\delta$ )

	1	2	3	C <sub>18</sub>	C <sub>19</sub>	Ref
	$\alpha$ -OH	$\alpha$ -OH	$\beta$ -OH	0.54	5.14	17
	$\beta$ -OH	$\beta$ -OH	$\alpha$ -OH	0.53	5.11	17
	$\alpha$ -CH <sub>2</sub> OH	-	$\beta$ -OH	0.54	5.02	15
	$\beta$ -CH <sub>2</sub> OH	-	$\alpha$ -OH	0.50	4.99	15
	$\alpha$ -CH <sub>2</sub> CH <sub>2</sub> OH	-	$\beta$ -OH	0.54	4.90	13b
	$\beta$ -CH <sub>2</sub> CH <sub>2</sub> OH	-	$\alpha$ -OH	0.51	4.88	13b
3	1 $\alpha$ -OH	2 $\alpha$ -(CH <sub>2</sub> ) <sub>4</sub> OH	$\beta$ -OH	0.54	5.00	this
3'	1 $\beta$ -OH	2 $\beta$ -(CH <sub>2</sub> ) <sub>4</sub> OH	$\alpha$ -OH	0.52	4.98	work

Thus, in only 11 steps from commercially available methyl 2-pyrone-3-carboxylate, two new vitamin D<sub>3</sub> analogues have been prepared, and the C,D-ring chiron 14 has been used to resolve  
5 racemic A-ring phosphine oxide 13.

**SCHEME IV**

Preliminary biological evaluation of synthetic diastereomers 3 and 3' involved measuring their relative binding affinities to rat vitamin D binding protein (DBP) and also to the vitamin D receptor of bovine thymus (Table III). Diastereomer 3 had significantly higher affinity than ED-71 (1) for the vitamin D binding protein, but it had extremely low affinity for the vitamin D receptor; whether this separation of binding affinities has important mechanistic and/or medicinal value remains to be established. Diastereomer 3', on the other hand, had lower affinity than ED-71 (1) for the vitamin D binding protein, but it had higher affinity than ED-71 (1) for the vitamin D receptor. Determining the impact of these differences on possible use of these new analogues for chemotherapy of osteoporosis requires further biological testing.

TABLE III.

RELATIVE BINDING AFFINITIES		
	<u>DBP</u>	<u>D RECEPTOR</u>
25(OH)-D <sub>3</sub>	90	---
1,25(OH) <sub>2</sub> -D <sub>3</sub>	1	1
Ed-71(1)	3.7	0.21
3	5.0	0.01
3'	1.9	0.28

Relative binding affinities of diastereomers 3 and 3' to the vitamin D binding protein and to the vitamin D receptor showed some unusual trends. Diastereomer 3' surprisingly bound much more effectively to the vitamin D receptor than did the established osteoporosis drug candidate ED-71 (1).

### EXAMPLES

#### General

Tetrahydrofuran and diethyl ether were distilled from benzophenone ketyl prior to use. Methylene chloride and triethylamine were distilled from calcium hydride immediately prior to use. Commercially available anhydrous solvents were used in other instances. All reagents were purchased from Aldrich Chemical Co. (Milwaukee, WI) and unless otherwise specified were used as received without further purification. All reactions were run in flame-dried flasks under nitrogen unless otherwise specified. FT-IR spectra were determined using a Perkin-Elmer Model 1600 FT-IR spectrophotometer. The <sup>1</sup>H NMR were recorded on a Varian XL-400 spectrometer and Bruker AMX-300 spectrometer operating at 400 and 300 MHz, respectively. The <sup>13</sup>C spectra were recorded on the same instruments operating at 100 and 75 MHz, respectively. High resolution mass spectra were obtained on a two sector-high-

resolution VG-70S mass spectrometer run at 70 eV. A Leco Corp. Model No. PG-200-HPC 13 Kbar apparatus was used for the high-pressure studies.

#### Silylated Vinylic Ether 7Z

- 5           To a 100 mL round-bottomed flask containing 2.1 g (17.5 mmol) of 1,6-hexanediol, 2.7 mL (19.2 mmol) of triethylamine, and 10 mg of N,N-dimethylaminopyridine in 35 mL  $\text{CH}_2\text{Cl}_2$  was added 5 mL (19.2 mmol) of t-butylchlorodiphenylsilane.
- 10          The reaction was stirred at room temperature for 12 h, or until complete by TLC. The reaction was quenched with 10 mL water, the organic layer was separated, and the aqueous layer was washed with  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were dried
- 15          over  $\text{MgSO}_4$ , filtered, and concentrated. The crude product was purified by column chromatography (10-20% EtOAc/Hexane) to afford 3.73 g (10.45 mmol, 60% yield) of the monosilated product as a clear oil.
- 20           To a 250 mL round-bottomed flask containing 10.14 mL (125.4 mmol) of pyridine in 50 mL of  $\text{CH}_2\text{Cl}_2$  was slowly added 6.27 g (62.7 mmol) of chromium trioxide. The resultant deep burgundy solution was stirred for 15 minutes at room
- 25          temperature. At the end of this period, a solution of the above monosilated diol in 50 mL  $\text{CH}_2\text{Cl}_2$  was added via cannula. A tarry, black



deposit separated immediately. This mixture was stirred for 1h at which time the  $\text{CH}_2\text{Cl}_2$  was removed on a rotary evaporator and the tar was diluted with  $\text{Et}_2\text{O}$ . This heterogeneous mixture was filtered  
5 through silica gel to give a yellow liquid which was concentrated. The crude product was purified by column chromatography (5% EtOAc/Hexane) to give 3.17 g (8.9 mmol, 85% yield) of the aldehyde as a clear oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.74 (s, 1H),  
10 7.675 (m, 4H), 7.40 (m, 6H), 3.66 (t,  $J=6.2$  Hz, 2H), 2.34 (m, 2H), 1.58 (m, 4H), 1.41 (m, 2H), 1.04 (s, 9H), IR ( $\text{CHCl}_3$ )  $3013\text{ cm}^{-1}$ ,  $2931\text{ cm}^{-1}$ ,  $1713\text{ cm}^{-1}$ .

The above aldehyde was then diluted with 20  
15 mL of benzene and 1.64 mL (11.75 mmol) of triethylamine. The resulting mixture was cooled to  $0^\circ\text{C}$  and 2.45 mL (10.68 mmol) of t-butyldimethylsilyl triflate was added. The reaction was allowed to warm to room temperature  
20 and stirred for 1 h. The reaction was quenched with brine and diluted with  $\text{Et}_2\text{O}$ . The organic layer was separated, and the aqueous layer was washed with  $\text{Et}_2\text{O}$ . The combined organic layers were dried over  $\text{MgSO}_4$ , filtered, and concentrated. The  
25 crude product was purified by column chromatography (Hexane) or silica gel that was slurry-packed with 1% triethylamine/hexane. The silylated vinylic ether 7Z (1.67 g, 3.56 mmol, 40%

yield) was a clear oil;  $R_f=0.8$  (25% EtOAc/Hexane);  
 $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 (m, 4H), 7.41 (m,  
6H), 6.17 (dt,  $J=5.9, 1.5$  Hz, 1H), 4.43 (dd,  
5  $J=7.4, 5.9$  Hz, 1H), 3.61 (t,  $J=6.6$  Hz, 2H), 2.09  
(ddt,  $J=14.7, 7.4, 1.5$  Hz, 2H), 1.54 (m, 2H), 1.37  
(m, 2H), 0.92 (s, 9H), 0.12 (s, 6H);  $^{13}\text{C}$  NMR (75  
MHz,  $\text{CDCl}_3$ )  $\delta$  138.50, 135.54 (4), 134.15 (2),  
129.50, 129.43, 127.55 (2), 127.53, 110.54, 63.93,  
32.31, 26.87 (3), 25.99 (3), 25.80, 25.66, 23.36,  
10 19.22, -2.92, -5.36; IR ( $\text{CHCl}_3$ ) 3013, 2931, 1654,  
1108  $\text{cm}^{-1}$ ; HRMS m/e calcd. for  $\text{C}_{24}\text{H}_{35}\text{O}_2\text{Si}_2$  411.2176,  
found 411.2179.

#### Cycloadduct 8

A 12 cm piece of 3/8" heat shrinkable teflon  
15 tubing (Ace Glass cat. #12685-40) was sealed on  
one end with a glass dowel plug by using a heat  
gun. To this 500.0 mg (3.24 mmol) of methyl 2-  
pyrone-3-carboxylate (Aldrich), 2g (4.26 mmol) of  
silylated vinylic ether 7Z, 10 mg of barium  
20 carbonate, and 2 mL of dry  $\text{CH}_2\text{Cl}_2$  was added. The  
open end of tubing was then sealed in a similar  
fashion with a second glass dowel plug. This  
'sealed tube' was the pressurized at 10-11 Kbar at  
room temperature for 4 days. The reaction mixture  
25 was concentrated on a rotary evaporator and the  
residue was purified by column chromatography (5%  
EtOAc/Hexane) to give 1.21 g (1.94 mmol, 60%) of

the cycloadduct **8** as a clear oil;  $R_f=0.58$  (25% EtOAc/Hexane);  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 (m, 4H), 7.41 (m, 6H), 6.78 (dd,  $J=7.8, 2.8$  Hz, 1H), 6.46 (dd,  $J=7.8, 5.1$  Hz, 1H), 5.09 (ddd,  $J=5.1, 3.8, 1.0$  Hz, 1H), 4.71 (dd,  $J=7.6, 1.00$  Hz, 1H), 3.89 (s, 1H), 3.66 (t,  $J=6.1$  Hz, 3H), 2.35 (ddd,  $J=7.6, 3.8, 2.8$  Hz, 1H), 1.56 (m, 2H), 1.26 (m, 2H), 1.06 (s, 9H), 0.91 (m, 2H), 0.78 (s, 9H), 0.012 (s, 3H), 0.006 (s, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  168.93, 167.51, 135.51 (4), 133.70 (2), 130.46, 129.53 (2), 128.64, 127.54 (4), 76.12, 69.36, 63.12, 52.7, 44.72, 32.37, 27.09, 26.75 (3), 25.64 (3), 25.56, 25.31, 23.34, 19.09, 18.04, -3.90, -5.03, IR ( $\text{CHCl}_3$ ) 1760, 1743  $\text{cm}^{-1}$ ; HRMS  $m/e$  calcd. for  $\text{C}_{31}\text{H}_{41}\text{O}_6\text{Si}_2$  565.2442, found 565.2450.

#### Mixed Malonate **9**

To a 25 mL round-bottomed flask with 500 mg (0.80 mmol) of cycloadduct **8** and 2 mL of  $\text{CH}_2\text{Cl}_2$  at  $0^\circ\text{C}$  was added dropwise, via syringe, 962  $\mu\text{L}$  of a freshly made 1.0 M solution of lithium allyloxide in allyl alcohol. The reaction mixture was allowed to warm to room temperature after the addition. Reaction was complete by TLC after 2 hours. The mixture was quenched with 2 mL aq.  $\text{NH}_4\text{Cl}$  and extracted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was dried with  $\text{MgSO}_4$ , filtered, and concentrated on a rotary evaporator. The residue was purified by

column chromatography (0-20% EtOAc/Hexane) to give 410 mg (0.60 mmol, 75%) of the desired malonate as a clear oil;  $R_f$ =0.42 (25% EtOAc/Hexane);  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.68 (m, 4H), 7.41 (m, 6H), 5.96 (s, 2H), 5.83 (ddt,  $J$ =17.2, 10.5, 5.6 Hz, 1H), 5.36 (dd,  $J$ =17.2, 1.5 Hz, 1H), 5.22 (dd,  $J$ =10.5, 1.5 Hz, 1H), 4.76 (s, 1H), 4.63 (ddt,  $J$ =13.3, 5.6, 1.4 Hz, 1H), 4.51 (ddt,  $J$ =13.3, 5.6, 1.4 Hz, 1H), 4.02 (t,  $J$ =8.6 Hz, 1H), 3.74 (s, 3H), 3.69 (t,  $J$ =6.1 Hz, 2H), 1.71 (m, 2H), 1.64 (m, 2H), 1.57 (s, 1H), 1.28 (m, 2H), 1.05 (s, 9H), 0.81 (s, 9H), 0.07 (s, 3H), -0.06 (s, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  169.11, 167.95, 135.41 (4), 134.07 (2), 133.89, 131.17, 129.34 (2), 127.44 (4), 122.47, 118.43, 71.70, 68.64, 65.72, 63.89, 61.38, 52.57, 46.04, 32.45, 26.76 (3), 25.94 (3), 23.25, 19.04, 18.27, 14.02, -3.79, -4.44; IR ( $\text{CHCl}_3$ )  $1737\text{ cm}^{-1}$ ; HRMS  $m/e$  calcd. for  $\text{C}_{34}\text{H}_{47}\text{O}_7\text{Si}_2$  623.2860, found 623.2865.

To a 25 mL round-bottomed flask with 380 mg (0.56 mmol) of the allyl ester alcohol, 78  $\mu\text{L}$  (0.67 mmol) of 2,6-lutidine, and 1.5 mL of  $\text{CH}_2\text{Cl}_2$  at  $0^\circ\text{C}$  was added 154  $\mu\text{L}$  (0.67 mmol) of *t*-butyldimethylsilyl trifluoroethanesulfonate dropwise via syringe. The reaction was complete by TLC after 10 minutes. The reaction was quenched at  $0^\circ\text{C}$  with 1 mL water and allowed to warm to room temperature. Extraction with  $\text{CH}_2\text{Cl}_2$

followed by drying with  $\text{MgSO}_4$ , filtration, and concentration afforded a viscous oil which was purified by column chromatography (5% EtOAc/Hexane) giving 390 mg (0.49 mmol, 87%) of O-silylated mixed malonate 9 as a clear oil;  $R_f=0.6$  (25% EtOAc/Hexane);  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.68 (m, 4H), 7.41 (m, 6H), 5.87 (d,  $J=2.68$  Hz, 2H), 5.83 (ddt,  $J=17.2, 10.5, 5.6$  Hz, 1H), 5.36 (dd,  $J=17.2, 1.5$  Hz, 1H), 5.22 (dd,  $J=10.5, 1.5$  Hz, 1H), 4.76 (s, 1H), 4.63 (ddt,  $J=13.3, 5.6, 1.4$  Hz, 1H), 4.51 (ddt,  $J=13.3, 5.6, 1.4$  Hz, 1H), 4.13 (d,  $J=9.2$  Hz, 1H), 3.74 (s, 3H), 3.69 (t,  $J=6.1$  Hz, 2H), 1.76 (m, 2H), 1.61 (m, 2H), 1.55 (s, 1H), 1.28 (m, 2H), 1.06 (s, 9H), 0.88 (s, 9H), 0.83 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H), 0.04 (s, 3H), - 0.06 (s, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  169.27, 167.96, 135.45 (4), 133.99 (2), 133.97, 131.33, 129.38 (2), 127.48 (4), 121.83, 118.43, 71.70, 69.16, 65.69, 64.00, 61.47, 52.52, 46.10, 32.67, 26.81 (3), 25.99 (3), 25.80 (3), 23.25, 19.10, 18.35, 17.99, 14.11, -3.83, -4.20, -4.34, -4.70; IR ( $\text{CHCl}_3$ )  $1737\text{ cm}^{-1}$ ; HRMS  $m/e$  calcd. for  $\text{C}_{40}\text{H}_{61}\text{O}_7\text{Si}_3$  737.3725, found 737.33730.

#### Cyclohexene Ester 10

A mixture of 380 mg (0.48 mmol) of malonate 9, 23  $\mu\text{L}$  (0.60 mmol) formic acid, 87  $\mu\text{L}$  (0.62 mmol) triethylamine, 10 mg (0.04 mmol)

triphenylphosphine, and 2 mg (0.01 mmol) palladium acetate in 1.5 mL dioxane was sealed in a 5 mL hydrolysis tube and heated at 100°C for 12 h. After evaporation of dioxane, 1 N HCl (1mL) was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 mL x 2). The organic solution was washed with saturated NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>, filtered, and concentrated. The oily residue was purified by column chromatography (0-10% EtOAc/Hexane) to give 310 mg (0.44 mmol, 92%) of cyclohexene ester 10 as a clear oil: R<sub>f</sub>=0.50 (25% EtOAc/Hexane); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.68 (m, 4H), 7.41 (m, 6H), 6.87 (t, J=1.5 Hz, 1H), 5.76 (s, 1H), 4.72 (s, 1H), 4.16 (m, 1H), 3.99 (m, 1H), 3.74 (s, 3H), 3.69 (t, J=6.1 Hz, 2H), 2.60 (dt, J=14.3, 5.6 Hz, 1H), 2.10 (ddd, J=16.9, 8.4, 1.5 Hz, 1H), 1.58 (m, 2H), 1.55 (s, 1H), 1.38 (m, 2H), 1.26 (m, 2H), 1.05 (s, 9H), 0.89 (s, 9H), 0.83 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H), -0.07 (s, 3H), -0.09 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.01, 135.51 (4), 134.05 (2), 133.16, 132.35, 129.45 (2), 127.55 (4), 66.89, 64.16, 51.50, 47.43, 33.1, 26.87, 25.95, 25.92, 25.89, 25.84, 25.68, 23.31, 19.17, 18.42, 18.06, -4.09, -4.37, -4.74, -5.39; IR (CHCl<sub>3</sub>) 1713 cm<sup>-1</sup>; HRMS m/e calcd. for C<sub>36</sub>H<sub>57</sub>O<sub>5</sub>Si<sub>3</sub> 653.3514, found 653.3516.

**Allylic Alcohol 11**

To a 25 mL round-bottomed flask containing 695 mg (0.98 mmol) of cyclohexene ester 10 in 8 mL toluene at -78°C was added 2.15 ml (2.15 mmol) of 1 M diisobutylaluminum hydride in toluene dropwise via syringe. The reaction was complete by TLC after 1h. The reaction was quenched by addition at -78°C of 5 mL of 2 M potassium sodium tartrate followed by dilution with 10 mL EtOAc. After the mixture was allowed to warm to room temperature and stirred for 0.5 h, two layers were visible. These were separated and the aqueous layer was washed with EtOAc. The combined organic fractions were washed with water, and brine, and dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (0-25% EtOAc/Hexane) to give 518 mg (0.76 mmol, 77%) of allylic alcohol 11 as a clear oil: R<sub>f</sub>=0.35 (25% EtOAc/Hexane); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.68 (m, 4H), 7.41 (m, 6H), 5.51 (t, J=1.5 Hz, 1H), 4.80 (s, 1H), 4.22 (d, J=12.0 Hz, 1H), 4.16 (m, 1H), 3.99 (m, 1H), 3.74 (s, 3H), 3.69 (t, J=6.1 Hz, 2H), 2.60 (dt, J=14.3, 5.6 Hz, 1H), 2.10 (ddd, J=16.9, 8.4, 1.5 Hz, 1H), 1.58 (m, 2H), 1.55 (s, 1H), 1.38 (m, 2H), 1.26 (m, 2H), 1.05 (s, 9H), 0.89 (s, 9H), 0.83 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H), -0.07 (s, 3H), -0.09 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 137.81, 135.51 (4), 134.04 (2),

129.47 (2), 127.55 (4), 122.65, 70.03, 68.32,  
65.68, 63.77, 46.36, 33.11, 31.28, 26.85 (3),  
25.90 (3), 25.82 (3), 25.51, 25.43, 24.52, 24.03,  
19.21, 18.06, -4.20, -4.82 (2), -4.92; IR (CHCl<sub>3</sub>)  
5 3401, 1713 cm<sup>-1</sup>; HRMS m/e calcd. for C<sub>34</sub>H<sub>57</sub>O<sub>4</sub>Si<sub>3</sub>  
625.3565, found 625.3570.

### Z-Dienoate 12

To 510 mg (0.75 mmol) of allylic alcohol 11  
in a sealable hydrolysis tube was added 642 mg  
10 (2.2 mmol) triethylphenyl sulfinyl orthoacetate  
and 1.0 mg 2,4,6-trimethylbenzoic acid and 2 mL  
CH<sub>2</sub>Cl<sub>2</sub>. The tube was purged with argon and sealed,  
then heated at 100°C for 12h. The reaction  
mixture was concentrated. Crude <sup>1</sup>H NMR showed a  
15 >10:1 mixture of Z:E isomers. The crude product  
was purified via PTLC (10%EtOAc/Hexane) to give  
450 mg (0.60 mmol, 80%) of Z dienoate 12 as a  
clear oil; R<sub>f</sub>=0.61 (25% EtOAc/Hexane); <sup>1</sup>H NMR (400  
MHz, CDCl<sub>3</sub>) δ 7.68 (m, 4H), 7.41 (m, 6H), 5.61 (s,  
20 1H), 5.17 (t, J=1.8 Hz, 1H), 5.09 (t, J=1.3 Hz,  
1H) 4.55 (dd, J=5.5, 1.3 Hz, 2H), 4.12 (q, J=7.2  
Hz, 2H), 3.97 (t, J=3.8 Hz, 1H), 3.66 (t, J=6.1  
Hz, 2H), 2.48 (dd, J=5.5, 1.4 Hz, 1H), 2.15 (dd,  
J=3.8, 1.7 Hz, 1H), 1.70 (m, 1H), 1.58 (m, 2H),  
25 1.55 (s, 1H), 1.38 (m, 2H), 1.26 (m, 2H), 1.04 (s,  
9H), 0.87 (s, 18H), 0.05 (s, 6H), 0.04 (s, 6H); <sup>13</sup>C  
NMR (75 MHz, CDCl<sub>3</sub>) δ 165.92, 157.09, 153.29,



145.39, 135.52 (4), 134.09 (2), 129.47 (2), 127.55  
(4), 117.17, 70.23, 63.91, 59.67, 50.54, 32.98,  
26.86 (3), 25.80 (3), 25.74 (3), 19.20, 18.18,  
17.98, 14.30, 14.13, -4.66, -4.83, -4.87, -5.17;  
5 IR (CHCl<sub>3</sub>) 3025, 2931, 1713 cm<sup>-1</sup>; HRMS m/e calcd.  
for C<sub>43</sub>H<sub>70</sub>O<sub>5</sub>Si<sub>3</sub> 750.4531, found 750.4538.

### Phosphine Oxide 13

To a 25 mL round-bottomed flask containing  
180 mg (0.24 mmol) of dienoate 12 in 2 mL toluene  
10 at -78°C was added dropwise 530 µL (0.53 mmol) of  
a 1 M solution of diisobutylaluminum hydride via  
syringe. After 1h the reaction was complete by  
TLC. The reaction was quenched at -78°C by  
addition of 2 mL of 2 N potassium sodium tartrate  
15 and dilution with 5 mL EtOAc. The mixture was  
allowed to warm to room temperature and stirred  
0.5 h until two distinct phases appeared. The  
organic phase was separated, and the aqueous phase  
was washed with EtOAc. The combined organic  
20 extracts were washed with water and brine, dried  
over MgSO<sub>4</sub>, filtered, and concentrated. The crude  
mixture was quickly purified by column  
chromatography (10-20% EtOAc/Hexane) to give 167  
mg (0.24 mmol) of the desired allylic alcohol.

25 To a 10 mL round-bottomed flask containing  
152 mg (1.14 mmol) N-chlorosuccinimide in 3 mL  
CH<sub>2</sub>Cl<sub>2</sub> at 0°C was added 90 mL (1.22 mmol) of

dimethyl sulfide via syringe. A white precipitate formed immediately upon addition. This mixture was cooled to  $-20^{\circ}\text{C}$  and stirred for 20 minutes. The above allylic alcohol in 2 mL  $\text{CH}_2\text{Cl}_2$  was then added  
5 to the heterogeneous mixture via cannula. The reaction was stirred for 0.5 h at  $-20^{\circ}\text{C}$  and then allowed to warm to room temperature and stirred for an additional 1 h. The organic layer was washed with water, brine, dried with  $\text{MgSO}_4$ ,  
10 filtered, and concentrated. The crude product was passed through florisil (5% EtOAc/Hexane) to afford 154 mg (0.21 mmol) of the desired allylic chloride as a yellow oil.

To a 10 mL round-bottomed flask containing  
15 the above allylic chloride in 2 mL THF at  $-78^{\circ}\text{C}$  was added dropwise via cannula a 0.5 M solution of potassium diphenylphosphide in THF. The addition was stopped once the red color persisted. After 1 h the reaction was allowed to slowly warm to  $0^{\circ}\text{C}$   
20 at which point it was complete by TLC. The reaction was quenched with 2 drops of water and the THF was removed. The residue was diluted with 2 mL  $\text{CH}_2\text{Cl}_2$  and 10 drops of 30%  $\text{H}_2\text{O}_2$  was added. After 1 h the reaction was diluted with  $\text{CH}_2\text{Cl}_2$  and  
25 water and the layers were separated. The organic phase was concentrated. The crude product was purified by column chromatography (25-50% EtOAc/Hexane) to give 121 mg (0.13 mmol, 54% from

Z-dienoate 12) of the phosphine oxide 13 as a clear oil:  $R_f=0.56$  (75% EtOAc/Hexane);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.74-7.36 (m, 20H), 5.3 (dd,  $J=15.1$  Hz, 6.6H), 5.11 (s, 1H), 4.75 (s, 1H), 4.42 (d,  $J=3.2$  Hz, 1H), 3.87 (dd,  $J=8.9$ , 4.9 Hz, 1H), 3.65 (t,  $J=6.6$  Hz, 3H), 3.40 (dt,  $J=15.1$ , 8.9 Hz, 1H), 3.14 (dt,  $J=16.0$ , 6.7 Hz, 1H), 2.4 (dd,  $J=13.3$ , 3.2 Hz, 1H), 2.06 (dd,  $J=14.2$ , 2.9 Hz, 1H), 1.56 (m, 1H), 1.53 (m, 2H), 1.43 (m, 2H), 1.35 (m, 2H), 1.04 (s, 9H), 0.88 (s, 9H), 0.82 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H), -0.01 (s, 3H), -0.03 (s, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  146.20 (2), 141.17, 135.50 (4), 134.06 (2), 131.71, 131.04, 130.92 (4), 129.45 (2), 128.63 (4), 128.47 (2), 127.53 (4), 114.39, 70.15, 63.90, 50.72, 32.97, 30.09, 26.83 (3), 25.79 (3), 25.05, 24.06, 19.18, 18.04, -4.58, -4.69, -4.89, -5.07; IR ( $\text{CHCl}_3$ ) 3025, 2954, 1472, 1255  $\text{cm}^{-1}$ ; HRMS  $m/e$  calcd. for  $\text{C}_{49}\text{H}_{68}\text{O}_4\text{Si}_3$  835.4163, found 835.4169.

## 20 Calcitriol Analogues 3 and 3'


To a 10 mL round-bottomed flask containing 95 mg (0.103 mmol) of phosphine oxide 13 in 1.4 mL of THF at  $-78^\circ\text{C}$  was added dropwise 67  $\mu\text{L}$  (0.103 mmol) of a 1.54 M solution of phenyllithium in THF. The resultant red solution was allowed to stir for 10 minutes. A solution of 20 mg (0.056 mmol) of C-D ring 14 in 1 mL of THF was added via cannula. The

reaction was complete after 1 h by TLC following disappearance of C-D ring. The reaction was quenched by addition of 1 mL 1:1  $\text{KHCO}_3$ /2 N potassium sodium tartrate. The layers were separated and the organic phase was washed with brine, dried over  $\text{MgSO}_4$ , filtered and concentrated. The crude product was rapidly purified by filtration through silica gel using 50% EtOAc/Hexane as solvent to give 47 mg (0.052 mmol, 50% yield) of the coupled product. The silyl ethers were cleaved by redissolving the product in 1 mL of THF and treating with 220  $\mu\text{L}$  (0.22 mmol) of tetrabutylammonium fluoride. After 24 h the reaction was diluted with water and the layers were separated, dried over  $\text{MgSO}_4$ , filtered and concentrated. The diastereomers were separated and purified by reverse phase HPLC (30-20%  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  on a C-18 semi-prep. column) to afford 1.1 mg (0.002 mmol, 4% yield) of analogue 3, and 4.4 mg (0.008 mmol, 16% yield) of analogue 3', both as white solids.  $^1\text{H}$  NMR of 3 (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.41 (d,  $J=11.6$  Hz, 1H), 6.02 (d,  $J=11.6$  Hz, 1H), 5.29 (s, 1H), 5.02 (s, 1H), 4.35 (s, 1H), 3.82 (m, 1H), 3.68 (t,  $J=6.1$  Hz, 2H), 2.78 (d,  $J=11.5$  Hz, 1H), 2.62 (dd,  $J=11.5$ , 3.5 Hz, 1H), 2.20 (dd,  $J=10.2$ , 3.5 Hz, 1H), 1.98 (m, 2H), 1.68-1.20 (m), 0.92 (s, 3H), 0.90 (s, 3H), 0.54 (s, 3H).  $^1\text{H}$  NMR of 3' (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.40 (d,

J=11.6 Hz, 1H), 5.98 (d, J=11.6 Hz, 1H), 5.27 (s, 1H), 4.98 (s, 1H), 4.38 (s, 1H), 3.87 (m, 1H), 3.68 (t, J=6.1 Hz, 2H), 2.82 (d, J=11.5 Hz, 1H), 2.65 (dd, J=11.5, 3.5 Hz, 1H), 2.24 (dd, J=10.2, 3.5 Hz, 1H), 1.68-1.20 (m), 0.92 (s, 3H), 0.90 (s, 3H), 0.52 (s, 3H); UV-Vis (MeOH)  $\lambda_{\text{max}}$  268 nm ( $\epsilon$  15,600); HRMS m/e calcd. for  $\text{C}_{31}\text{H}_{50}\text{O}_3$  470.3760, found 470.3771.

## 2-Fluorides

10           The above-described methods for producing the vitamin D<sub>3</sub> analogues with alcohols substituted in the 2-position can be readily modified to produce comparable analogues with fluorides substituted in the two position (18-21). Table IV lists the  
15 fluoride analogues of the present invention.

**TABLE IV****2-SUBSTITUTED FLUORIDES OF CALCITRIOL**

Position		
<u>3</u>	<u>2</u>	<u>1</u>
3 $\beta$	2 $\alpha$ -(CH <sub>2</sub> ) <sub>4</sub> F	1 $\alpha$
3 $\alpha$	2 $\beta$ -(CH <sub>2</sub> ) <sub>4</sub> F	1 $\beta$
3 $\beta$	2 $\alpha$ -(CH <sub>2</sub> ) <sub>3</sub> F	1 $\alpha$
3 $\alpha$	2 $\beta$ -(CH <sub>2</sub> ) <sub>3</sub> F	1 $\beta$

The following scientific articles and references have been cited throughout this application and the entire contents of each article or reference is hereby incorporated by reference.

#### Scientific Articles

1. Yamaguchi, K.; Matsumura, G.; Kagechika, H.; Azumaya, I.; Ito, Y.; Itai, A.; Shudo, K.; *J. Am. Chem. Soc.*, **1991**, *113*, 5474 and references therein.
2. Tilyard, M.W. in "Vitamin D: Gene Regulation, Structure-Function Analysis, and Clinical Applications", A.W. Norman, R. Bouillon, M. Thomasset, Eds., W. de Gruyter, NY, **1991**, p. 779.
3. Nordin, B.E.C.; Need, A.G.; Morris, H.A.; Horowitz, M. in "Vitamin D: Gene Regulation, Structure-Function Analysis, and Clinical Applications", A.W. Norman, R. Bouillon, M. Thomasset, Eds., W. de Gruyter, NY, **1991**, p. 787.
4. a) Nishii, Y.; Abe, S.; Kobayashi, T.; Okano, T.; Tsugawa, N.; Slatopolsky, E.; Brown, A.J.; Dusso, A.; Raisz, L.G. in "Vitamin D: Gene Regulation, Structure-Function Analysis, and Clinical Applications", A.W. Norman, R. Bouillon, R. Thomasset, Eds., W. de Gruyter, NY, **1991**, p. 294; b) Okano, T.; Tsugawa, N.; Masuda, S.; Takeuchi, A.; Kobayashi, T.; Takita, Y.; Nishii, Y.; *Biochem. Biophys. Res. Commun.*, **1989**, *163*, 1444; c) Miyamoto, K.; Murayama, E.; Ochi, K.; Watanabe, H.; Kubodera, N.; *Chem. Pharm. Bull.*, **1993**, *41*, 1111.
5. a) Posner, G.H.; Nelson, T.D.; Kinter, C.M.; Johnson, N.; *J. Org. Chem.*, **1992**, *57*, 4083; b) Posner, G.H.; Nelson, T.D.; Kinter, C.M., Afarinkia, K.; *Tetrahedron Lett.*, **1991**, *32*, 5295; c) Afarinkia, K.; Posner, G.H.; *Ibid*, **1992**, *33*, 7839; d) for a review, see Afarinkia, K.; Vinader, V.; Nelson, T.D.; Posner, G.H.; *Tetrahedron*, **1992**, *48*, 9111.

6. a) Gupta, R.B.; Frank, R.W.; *J. Am. Chem. Soc.*, 1987, 109, 5393; b) Jensen, F.; Foote, C.S.; *Ibid*, 1987, 109, 6376; c) Baran, J.; Mayr, H.; Ruster, V.; Klärner, F.G.; *J. Org. Chem.*, 1989, 54, 5016; d) Gassman, P.G.; Gorman, D.B.; *J. Am. Chem. Soc.*, 1990, 112, 8624; e) Reissig, H-U.; Hippeli, C.; Arnold, T.; *Chem. Ber.*, 1990, 123, 2403; f) Van Mele, B.; Huybrechts, G; *Int. J. Chem. Kinetics*, 1989, 21, 967; g) Sauer, J.; Lang, D.; Wiest, H.; *Chem. Ber.*, 1964, 97, 3208; g) cf. Li, Y.; Houk, K.N.; *J. Am. Chem. Soc.*, 1993, 115, 7478 and references therein.
7. a) Karplus, M.; *J. Chem. Phys.*, 1959, 30, 11; b) Karplus, J.; *J. Am. Chem. Soc.*, 1963, 85, 2870; c) Jackman, L.M.; Sternhell, S.; *Applications of NMR Spectroscopy in Organic Chemistry*, 2nd Ed.; Pergamon, NY, 1969.
8. a) Posner, G.H., Kinter, C.M.; *J. Org. Chem.*, 1990, 55, 3967; b) Posner, G.H.; Nelson, T.D.; *Tetrahedron*, 1990, 46, 4573; c) Posner, G.H.; Wettlaufer, D.G.; *J. Am. Chem. Soc.*, 1986, 108, 7373.
9. Moeller, K.D.; Tinao, L.V.; *J. Am. Chem. Soc.*, 1992, 114, 1033 and references therein.
10. 2-Pyrone, prone to rapid polymerization under thermal conditions, undergoes non-regioselective cycloadditions under very high pressure conditions (e.g. 18.5 Kbar): Markó, I.E.; Seres, P.; Swarbrick, T.M.; Staton, I.; Adams, H.; *Tetrahedron Lett.*, 1992, 33, 5649.
11. Posner, G.H.; Carry, J.-C.; Anjeh, T.E.N.; French, A.N.; *J. Org. Chem.*, 1992, 57, 7012.
12. Mandi, T.; Imaji, M.; Takada, H.; Kawata, M.; Nokami, J.; Tsuji, J.; *J. Org. Chem.*, 1989, 54, 5395.
13. a) Posner, G.H.; Crouch, R.D.; Kinter, C.M.; Carry, J.-C.; *J. Org. Chem.*, 1991, 56, 6981; b) Posner, G.H.; Dai, H.; *BioMed. Chem. Lett.*, 1993, 3, 1829.
14. Lythgoe, B.; Moran, T.A.; Nambudiry, M.E.N.; Tideswell, J.; Wright, P.W.; *J. Chem. Soc. Perkin Trans. 1*, 1978, 590.




15. Posner, G.H.; Nelson, T.C.; Guyton, K.Z.; Kensler, T.W.; *J. Med. Chem.*, 1992, 35, 3280.
- 5 16. Unpublished results of G.H. Posner and H. Liu.
17. Unpublished results of G.H. Posner, T. D. Nelson, and C.H. Oh.
18. Filler, R. et al. (Eds.); *Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications*, Elsevier Science Publishers, 1993.
- 10 19. Kobayashi, Y; Nakazawa, M.; Kumadaki, I., Taguchi, T., Ohshima, E.; Ikekawa, N.; Tanaka, Y.; DeLuca, H.F.; *Chem. Pharm. Bull.*, 1986, 34, 1568-1572.
- 15 20. Ohshima, E.; Sai, H.; Takatsuto, S.; Ikekawa, N.; Kobayashi, Y.; Tanaka, Y.; DeLuca, H.F.; *Chem. Pharm. Bull.*, 1984, 32, 3525-3531.
21. Oshida, L-i; Morisaki, M.; Ikekawa, N.; *Tetrahedron Lett.*, 1980, 21, 1755-1756.
- 20 While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on
- 25 the contrary is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

**WHAT IS CLAIMED IS:**


1. A vitamin D<sub>3</sub> analogue which includes a substituent in the 2-position selected from the group consisting of alcohols and fluorides.

5           2. The analogue of claim 1 wherein said substituent is  $-(CH_2)_4OH$ .

3. The analogue of claim 2 having the following structural formula:



4. The analogue of claim 2 having the following structural formula:



5. The analogue of claim 1 wherein said substituent is  $-(CH_2)_3F$ .

5           6. The analogue of claim 1 wherein said substituent is  $-(CH_2)_4F$ .

7. A method for the preparation of a vitamin  $D_3$  analogue which includes an alcohol substituent in the 2-position, comprising the steps of:

- 10           a) subjecting methyl 2-pyrone-3-carboxylate and a silylated vinylic ether to high pressure cycloaddition to form a bicycloadduct;
- b) reacting the bicycloadduct with lithium allyloxide to produce a mixed methyl allyl
- 15           malonate;

- c) decarboxylating the mixed methyl allyl malonate with palladium acetate to yield a cyclohexene ester;
- 5 d) silylating and reducing the cyclohexene ester to form an alcohol;
- e) subjecting the allylic alcohol to a Claisen rearrangement followed by spontaneous thermal sulfoxide elimination to form a Z-dienoate;
- 10 f) reacting the Z-dienoate with a hydride to form an allylic alcohol;
- g) reacting the allylic alcohol with N-chlorosuccinimide and dimethyl sulfide to form an allylic chloride;
- 15 h) reacting the allylic chloride with diphenylphosphide and then with hydrogen peroxide to form a phosphine oxide;
- i) reacting the phosphine oxide with phenyllithium to produce a conjugate base of the phosphine oxide;
- 20 j) coupling the conjugate base of phosphine oxide with a C,D-ring ketone to produce O-silylated derivatives of diastereomeric 2-(4'-hydroxylated) calcitriol analogues; and
- 25 k) separating and isolating the analogues.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/07595

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																										
IPC(6) :C07C 401/00 US CL :552/653 According to International Patent Classification (IPC) or to both national classification and IPC																										
<b>B. FIELDS SEARCHED</b>																										
Minimum documentation searched (classification system followed by classification symbols) U.S. : 552/653; C07C 401/00																										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																										
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																										
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																										
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
P, Y	US, A, 5,389,622 (POSNER ET AL.) 14 February 1995, see entire document.	1-4																								
X -- Y	JP, A, 6-41059 (NAKASOTO SEIYAKU KK) 15 February 1994, see entire document.	1, 2, 4 ----- 1-6																								
P, X	JOURNAL OF ORGANIC CHEMISTRY, VOLUME 59, NUMBER 25, ISSUED 16 DECEMBER 1994, POSNER ET AL., "STEREOCONTROLLED TOTAL SYNTHESIS OF CALCITRIOL DERIVATIVES: 1,25-DIHYDROXY-2-(4'-HYDROXYBUTYL) VITAMIN D ANALOGS OF AN OSTEOPOROSIS DRUG, PAGES 7855-7861.	1-4																								
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A</td> <td>document defining the general state of the art which is not considered to be part of particular relevance</td> <td>*X</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E</td> <td>earlier document published on or after the international filing date</td> <td>*Y</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*G</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be part of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G	document member of the same patent family	*O	document referring to an oral disclosure, use, exhibition or other means			*P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
*A	document defining the general state of the art which is not considered to be part of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G	document member of the same patent family																							
*O	document referring to an oral disclosure, use, exhibition or other means																									
*P	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search 18 JUNE 1995		Date of mailing of the international search report <b>29 SEP1995</b>																								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Kimberly J. Kestler</i> for KIMBERLY J. KESTLER jd Telephone No. (703) 308-1235																								